ArticleFrontiers in genetics2022
Molecular Subtyping of Cancer Based on Robust Graph Neural Network and Multi-Omics Data Integration.
Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Triad-LMF: a hierarchical low-rank multimodal fusion framework for robust cancer subtype classification using multi-omics data.BMC bioinformatics · 2026Article
- Deep learning in multi-omics integration for gastrointestinal cancer biomarker discovery.Frontiers in oncology · 2026Review
- IGCN: integrative graph convolution networks for patient level insights and biomarker discovery in multi-omics integration.Bioinformatics (Oxford, England) · 2025Article
- Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.Cancers · 2025Review
- Multi-Omics Integration for Liver Cancer Using Regression Analysis.Current issues in molecular biology · 2024Article
- HyperTMO: a trusted multi-omics integration framework based on hypergraph convolutional network for patient classification.Bioinformatics (Oxford, England) · 2024Article
- MOGAT: A Multi-Omics Integration Framework Using Graph Attention Networks for Cancer Subtype Prediction.International journal of molecular sciences · 2024Article
- Methods for multi-omic data integration in cancer research.Frontiers in genetics · 2024Review
- Review
- Article
- Identification of Cancer Driver Genes by Integrating Multiomics Data with Graph Neural Networks.Metabolites · 2023Article
- A survey on multi-omics-based cancer diagnosis using machine learning with the potential application in gastrointestinal cancer.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate molecular subtypes prediction of cancer patients is significant for personalized cancer diagnosis and treatments. Large amount of multi-omics data and the advancement of data-driven methods are expected to facilitate molecular subtyping of cancer. Most existing machine learning-based methods usually classify samples according to single omics data, fail to integrate multi-omics data to learn comprehensive representations of the samples, and ignore that information transfer and aggregation among samples can better represent them and ultimately help in classification. We propose a novel framework named multi-omics graph convolutional network (M-GCN) for molecular subtyping based on robust graph convolutional networks integrating multi-omics data. We first apply the Hilbert-Schmidt independence criterion least absolute shrinkage and selection operator (HSIC Lasso) to select the molecular subtype-related transcriptomic features and then construct a sample-sample similarity graph with low noise by using these features. Next, we take the selected gene expression, single nucleotide variants (SNV), and copy number variation (CNV) data as input and learn the multi-view representations of samples. On this basis, a robust variant of graph convolutional network (GCN) model is finally developed to obtain samples' new representations by aggregating their subgraphs. Experimental results of breast and stomach cancer demonstrate that the classification performance of M-GCN is superior to other existing methods. Moreover, the identified subtype-specific biomarkers are highly consistent with current clinical understanding and promising to assist accurate diagnosis and targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.